Neuland Laboratories Limited (NEULANDLAB)

Name: Neuland Laboratories Limited（NEULANDLAB）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-09-20

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

关键数据

市值: ₹293 billion
收入（截至 2026-03-31 财年）: ₹19.3B
净利润: ₹3.6B
毛利率: 51.0%
净利率: 18.8%

查看交互式图表与完整报表 →

年度利润表

利润表	2026-03-31	2025-03-31	2024-03-31	2023-03-31
总收入	₹19.3B	₹14.3B	₹15.2B	₹11.6B
毛利	₹9.8B	₹6.8B	₹7.8B	₹5.5B
营业利润（EBIT）	₹4.9B	₹2.7B	₹4.1B	₹2.3B
净利	₹3.6B	₹2.6B	₹3.0B	₹1.6B

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 NEULANDLAB 交互式查看器。 /companies/us/NEULANDLAB

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.